The estimated Net Worth of Chris Raanes is at least 2.78 百万$ dollars as of 1 October 2012. Chris Raanes owns over 4,719 units of ViewRay stock worth over 5,926$ and over the last 18 years Chris sold VRAY stock worth over 2,774,251$.
Chris has made over 47 trades of the ViewRay stock since 2007, according to the Form 4 filled with the SEC. Most recently Chris sold 4,719 units of VRAY stock worth 33,316$ on 1 October 2012.
The largest trade Chris's ever made was selling 76,000 units of ViewRay stock on 8 February 2007 worth over 1,368,000$. On average, Chris trades about 10,538 units every 37 days since 2007. As of 1 October 2012 Chris still owns at least 237,037 units of ViewRay stock.
You can see the complete history of Chris Raanes stock trades at the bottom of the page.
Chris's mailing address filed with the SEC is 1310, Chesapeake Terrace, Sunnyvale, Santa Clara County, California, 94089, United States.
Over the last 9 years, insiders at ViewRay have traded over 157,178,869$ worth of ViewRay stock and bought 23,644,461 units worth 89,494,703$ . The most active insiders traders include David P Bonita、International Ltd Fosun、Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of 20,317$. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth 1,535$.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: